BACKGROUND AND OBJECTIVE: Vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) are important factors in angiogenesis. These factors function in the angiogenesis of lung cancers. The aim of this study is to determine the changes in serum VEGF and MMP-9 after patients with NSCLC were subjected to lobectomy. The aim of this study is also to compare the differences in the changes observed between video-assisted thoracoscopic surgery (VATS) and traditional open surgery (TOS). METHODS: A total of 43 consecutive patients with NSCLC were recruited from October 2010 to August 2012. All of these patients underwent lobectomy and systematic mediastinal lymphadenectomy. Blood was drawn from these patients to measure the serum levels of VEGF and MMP-9 in the morning before surgery and on postoperative days 1, 2, 3, and 7 (POD1, POD2, POD3, and POD7, respectively). Perioperative variations in serum VEGF and MMP-9 were also observed. Using different surgical options, we divided the patients into two groups: VATS group (25 patients) and TOS group (18 patients). The differences in the changes in serum VEGF and MMP-9 were then compared between the two groups. RESULTS: After surgery, the serum VEGF and MMP-9 of patients with NSCLC initially increased and subsequently decreased. The peak levels were observed on POD2 and POD3, and these levels were significantly higher than the preoperative levels (P=0.031, P=0.020). On POD7, the serum VEGF and MMP-9 remained higher than the preoperative levels. In VATS and TOS groups, the serum VEGF and MMP-9 levels also initially increased and subsequently decreased. The TOS group showed a more evident variation. However, no significant statistical differences in the changes of VEGF and MMP-9 were found between the two groups (F=2.022, P=0.163; F=1.703, P=0.199). CONCLUSIONS: Serum VEGF and MMP-9 remarkably increase in TOS group and VATS group. Although the serum level of VEGF an MMP-9 in TOS group were higher than that in VATS group. But no significant difference was observed between VATS and TOS group.
BACKGROUND AND OBJECTIVE:Vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) are important factors in angiogenesis. These factors function in the angiogenesis of lung cancers. The aim of this study is to determine the changes in serum VEGF and MMP-9 after patients with NSCLC were subjected to lobectomy. The aim of this study is also to compare the differences in the changes observed between video-assisted thoracoscopic surgery (VATS) and traditional open surgery (TOS). METHODS: A total of 43 consecutive patients with NSCLC were recruited from October 2010 to August 2012. All of these patients underwent lobectomy and systematic mediastinal lymphadenectomy. Blood was drawn from these patients to measure the serum levels of VEGF and MMP-9 in the morning before surgery and on postoperative days 1, 2, 3, and 7 (POD1, POD2, POD3, and POD7, respectively). Perioperative variations in serum VEGF and MMP-9 were also observed. Using different surgical options, we divided the patients into two groups: VATS group (25 patients) and TOS group (18 patients). The differences in the changes in serum VEGF and MMP-9 were then compared between the two groups. RESULTS: After surgery, the serum VEGF and MMP-9 of patients with NSCLC initially increased and subsequently decreased. The peak levels were observed on POD2 and POD3, and these levels were significantly higher than the preoperative levels (P=0.031, P=0.020). On POD7, the serum VEGF and MMP-9 remained higher than the preoperative levels. In VATS and TOS groups, the serum VEGF and MMP-9 levels also initially increased and subsequently decreased. The TOS group showed a more evident variation. However, no significant statistical differences in the changes of VEGF and MMP-9 were found between the two groups (F=2.022, P=0.163; F=1.703, P=0.199). CONCLUSIONS: Serum VEGF and MMP-9 remarkably increase in TOS group and VATS group. Although the serum level of VEGF an MMP-9 in TOS group were higher than that in VATS group. But no significant difference was observed between VATS and TOS group.
所有数据均以Mean±SD表示,使用软件SPSS 17.0进行数据统计学分析,两组人群资料差异用χ2检验或两独立样本t检验,两组间不同时间点VEGF、MMP-9水平差异采用两独立样本t检验或者重复测量数据的方差分析。P < 0.05为差异具有统计学意义。VATS组及TOS组患者临床及手术资料Clinical and surgical characteristics of patients of VATS and TOS group
Clinical and surgical characteristics of patients of VATS and TOS group
VATS group
TOS group
P
LUL: left upper lobe; LLL: left lower lobe; RUL: right upper lobe; RML: right middle lobe; RLL: right lower lobe; VATS: video-assisted thoracoscopic surgery; TOS: traditional open surgery; M: Male; F: Female; NS indicates lack of significant differences.
Numbers
25
18
Age (yr)
61.56±10.2
61.44±9.8
NS
Gender (M/F)
15/10
10/8
FEV1 (L)
2.49±0.68
2.49±0.61
NS
Tumor diameter (cm)
3.52±1.17
3.82±1.89
NS
Duration of surgery (min)
160.6±48.03
208.1±83.9
NS
Tumor location
LUL
5
9
LLL
5
5
RUL
11
2
RML
2
0
RLL
2
2
Histology
Adenocarcinoma
18
13
Squamous cell
6
5
Large cell
1
0
TNM stage
Ⅰ
18
9
Ⅱ
2
4
Ⅲa
5
5
Numbers of lymph nodes dissected
19.6±9.2
16.6±8.6
NS
Groups of lymph nodes dissected
5.16±1.03
4.89±1.13
NS
NSCLC患者围手术期血清VEGF及MMP-9水平的变化。Time 1:术前;Time 2:术后第1天;Time 3:术后第2天;Time 4:术后第3天;Time 5:术后第7天。Changes of perioperative seral VEGF and MMP-9 levels for NSCLCpatients. Time 1: the day before surgery; Time 2: the first day after surgery; Time 3: the second day after surgery; Time 4: the third day after surgery; time 5: the seventh day after surgery. VEGF: vascular endothelial growth factor; MMP-9: matrix metalloproteinase-9. NSCLC: non-small cell lung cancer.
围手术期血清VEGF及MMP-9水平的变化(图 1)
将所有入组患者围手术期VEGF及MMP-9水平的变化进行统计学分析。NSCLC患者术后血清VEGF水平呈先升高后下降的趋势,术后第2天达到峰值浓度,并且与术前相比有明显统计学差异(P=0.031),到术后第7天时,VEGF水平虽较前下降,但仍高于术前水平。NSCLC患者术后MMP-9水平呈逐渐升高的趋势,于术后第7天时较前略下降。与术前水平比较,术后第3天及第7天MMP-9水平均明显高于术前(P=0.020, P=0.034)。VATS组及TOS组围手术期血清VEGF、MMP-9水平变化的比较。Time 1:术前;Time 2:术后第1天;Time 3:术后第2天;Time 4:术后第3天;Time 5:术后第7天。Comparison of the changes of perioperative seral VEGF and MMP-9 levels between VATS group and OT group. Time 1: the day before surgery; Time 2: the first day after surgery; Time 3: the second day after surgery; Time 4: the third day after surgery; Time 5: the seventh day after surgery.
Authors: G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan Journal: Nat Cell Biol Date: 2000-10 Impact factor: 28.824
Authors: Calvin S H Ng; Song Wan; Connie W C Hui; Innes Y P Wan; Tak Wai Lee; Malcolm J Underwood; Anthony P C Yim Journal: Eur J Cardiothorac Surg Date: 2006-11-21 Impact factor: 4.191
Authors: Eloisa Jantus-Lewintre; Elena Sanmartín; Rafael Sirera; Ana Blasco; José Javier Sanchez; Miquel Tarón; Rafael Rosell; Carlos Camps Journal: Lung Cancer Date: 2011-04-09 Impact factor: 5.705
Authors: E Laack; A Köhler; C Kugler; T Dierlamm; C Knuffmann; G Vohwinkel; A Niestroy; N Dahlmann; A Peters; J Berger; W Fiedler; D K Hossfeld Journal: Ann Oncol Date: 2002-10 Impact factor: 32.976
Authors: Bryan A Whitson; Rafael S Andrade; Adam Boettcher; Ricardo Bardales; Robert A Kratzke; Peter S Dahlberg; Michael A Maddaus Journal: Ann Thorac Surg Date: 2007-06 Impact factor: 4.330